Open AccessEnoxaparin in non-ST segment elevation acute coronary syndromes: duration of therapy is essential to benefit
Author(s) -
Philippe Gabríel Steg,
Jean-Michel Juliard
Publication year - 2004
Publication title -
european heart journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.336
H-Index - 293
eISSN - 1522-9645
pISSN - 0195-668X
DOI - 10.1016/j.ehj.2004.07.028
Subject(s) - medicine , antithrombotic , heparin , partial thromboplastin time , tirofiban , context (archaeology) , intensive care medicine , discovery and development of direct thrombin inhibitors , acute coronary syndrome , pharmacodynamics , aspirin , anticoagulant , clinical trial , bivalirudin , low molecular weight heparin , percutaneous coronary intervention , pharmacokinetics , platelet , thrombin , myocardial infarction , paleontology , biology
lia ssi Yet, it is a difficult anticoagulant to manage, largely be-cause of a narrow therapeutic window therefore requiring 2 days after initiating treatment, with the attendant risks able so far mostly pertained to patients initially managed in a conservative fashion and there has been a clear LMWH in the context of PCI. Yet, the actual evidence antagonist to effectively reverse the action of LMWH was viewed with concern. 0195-668X/ $- see front matter c 2004 Published by Elsevier Ltd on behalf of The European Society of Cardiology. doi:10.1016/j.ehj.2004.07.028 P.G. Steg has been a consultant, a speaker and has received research grants from Aventis Pharma. doi:10.1016/j.ehj.2004.06.028
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom